Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Patent
1994-03-23
1996-02-20
Bernhardt, Emily
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
544374, 544398, 544401, A61K 31495, C07D295096
Patent
active
054929130
ABSTRACT:
The compounds are N-(unsubstituted or substituted) N'-benzylpiperazine compounds and pharmaceutically tolerable salts thereof, useful for treating neuronal disorders resulting from the dysfunctioning of oxidative metabolism.
A compound disclosed is: N-ethyl N'-(2-hydroxy-3,4- dimethoxybenzyl)-piperazine and its dihydrochloride.
REFERENCES:
patent: 5142053 (1992-08-01), Souvie
patent: 5281595 (1994-01-01), Lange et al.
patent: 5283246 (1994-02-01), Regnier et al.
Ohtaka et al, Chem. Pharm. Bull 37 p. 3122 (1989).
Bailey et al, Synlett p. 79 (1994).
Halliwell, et al., Oxygen radicals and the nervous system, TINS, Jan. 1985, pp. 22-26.
Bondy, et al., Review Article entitled: "The Relationship Between Excitotoxicity and Oxidative Stress in the Central Nervous System", Free Radical Biology & Medicine, vol. 14, (1993), pp. 633-642.
Stadtman, Protein Oxidation and Aging, Science, vol. 257, 28 Aug. 1992, pp. 1220-1224.
Bogaert, et al., Original Contribution entitled: "Postischemic Inhibition of Cerebral Cortex Pyruvate Dehydrogenase", Free Radical Biology & Medicine, vol. 16, No. 6, (1994), pp. 811-820.
A. Hartley, et al., Iron induced oxidative stress andmitochondrial dysfunction: relevance to Parkinson's disease, Brain Research 627, (1993), pp. 349-353.
G. Fiskum, et al., LV-4. Brain Protein Oxidation and Inhibition of Pyruvate Dehydrogenase Following Canine Cardiac Arrest and Resuscitation, Journal of Cerebral Blood Flow and Metabolism, The International Society of Cerebral Blood Flow and Metabolism, vol. 13, Suppl. 1 (1993), p. S567.
C. D. Smith, et al., Excess brain protein oxidation and enzyme dysfunction in normal aging and in Alzheimer disease, Proc. Natl. Acad. Sci. USA, vol. 88 (Dec. 1991), Medical Sciences, pp. 10540-10543.
Cao, et al., .alpha.-Phenyl-ter-butyl-nitrone reduces cortical infarct and edema in rats subjected to focal ischemia, Brain Research 644 (1994), pp. 267-272.
Carney, et al., Reversal of age-related increase in brain protein oxidation, decrease in enzyme activity, and loss in temporal and spatial memory by chronic administration of the spintrapping compound N-tert-butyl-.alpha.-phenylnitrone, Proc. Natl. Acad. Sci. USA, vol. 88 (May 1991), Neurobiology, pp. 3633-3636.
Dean, et al., Hypothesis: a damaging role in aging for reactive protein oxidation products?, Mutation Research 275, (1992), pp. 387-393.
Faden, et al., Pharmacological strategies in CNS trauma, TIPS, Jan. 1992, vol. 13, pp. 29-35.
Hall, et al., Effects of the 21-aminosteroid U74006F on experimental head injury in mice, J Neurosurg 68 (1988), pp. 456-461.
Lepagnol Jean
Rolland Yves
Testa Bernard
Tillement Jean-Paul
Wierzbicki Michel
Adir et Compagnie
Bernhardt Emily
Hueschen Gordon W.
LandOfFree
N-benzylpiperazine compounds does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with N-benzylpiperazine compounds, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and N-benzylpiperazine compounds will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1356025